Tasigna
E584154
Tasigna is a prescription tyrosine kinase inhibitor used primarily to treat certain types of Philadelphia chromosome–positive chronic myeloid leukemia (CML) in adults and children.
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
anticancer drug
ⓘ
pharmaceutical drug ⓘ tyrosine kinase inhibitor ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| contraindicatedWith | strong CYP3A4 inhibitors ⓘ |
| developedBy | Novartis NERFINISHED ⓘ |
| dosageForm | capsule ⓘ |
| generation | second-generation BCR-ABL tyrosine kinase inhibitor ⓘ |
| hasActiveIngredient | nilotinib ⓘ |
| hasATCCode | L01EA03 ⓘ |
| hasBlackBoxWarning |
QT prolongation
ⓘ
sudden death risk ⓘ |
| hasBoxedWarningRegion | United States NERFINISHED ⓘ |
| hasChemicalClass | aminopyrimidine derivative ⓘ |
| hasGenericName | nilotinib ⓘ |
| hasPregnancyCategory | D (US, historical classification) ⓘ |
| hasTradeName | Tasigna NERFINISHED ⓘ |
| indicatedFor |
Ph+ CML in accelerated phase
ⓘ
Ph+ CML in chronic phase ⓘ Philadelphia chromosome–positive chronic myeloid leukemia ⓘ adult patients with Ph+ CML ⓘ pediatric patients with Ph+ CML ⓘ |
| isSecondGeneration | true ⓘ |
| mayCause |
QT interval prolongation
ⓘ
elevated lipase ⓘ elevated liver enzymes ⓘ headache ⓘ hyperglycemia ⓘ myelosuppression ⓘ nausea ⓘ pruritus ⓘ rash ⓘ |
| metabolizedBy | CYP3A4 NERFINISHED ⓘ |
| reduces | leukemic cell growth ⓘ |
| regulates | BCR-ABL–mediated cell proliferation ⓘ |
| requiresFastingAdministration | true ⓘ |
| requiresMonitoring |
complete blood counts
ⓘ
electrocardiogram ⓘ liver function tests ⓘ serum electrolytes ⓘ |
| routeOfAdministration | oral ⓘ |
| targets |
ABL1
NERFINISHED
ⓘ
BCR-ABL tyrosine kinase NERFINISHED ⓘ PDGFR NERFINISHED ⓘ c-KIT NERFINISHED ⓘ |
| usedFor |
treatment of imatinib-intolerant Ph+ CML
ⓘ
treatment of imatinib-resistant Ph+ CML ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.